Physician profile
Daniel Cotter
NPI 1003018102
$48,022.34
in general payments reported to CMS, 2019-2025
22 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,888 · 2020: $289 · 2021: $715 · 2022: $15K · 2023: $26K · 2024: $2,704 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $3,842 · Travel and Lodging: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,260.00 |
| Food and Beverage | $3,842.37 |
| Travel and Lodging | $1,205.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $39,645.00 | 2022-2023 | Hillrom - Retinavue 700 Imager, Hillrom - Retinavue Network |
| Alcon Vision LLC | $2,380.51 | 2019-2025 | Clareon, Rocklatan, Simbrinza |
| Abbvie INC. | $1,156.78 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Biotissue Holdings INC. | $1,055.23 | 2019-2024 | |
| Sight Sciences, INC. | $925.68 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $559.24 | 2019-2025 | Cequa, Xelpros |
| Allergan, INC. | $528.00 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $442.54 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $271.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $268.92 | 2019-2023 | |
| Glaukos Corporation | $141.51 | 2025 | Idosetr |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $104.99 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $97.70 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $90.06 | 2024-2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $84.46 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $43.15 | 2025 | Oxervate |
| Astellas Pharma US INC | $24.44 | 2023 | |
| Thea Pharma INC. | $23.97 | 2025 | Iyuzeh |
| Shire North American Group INC | $19.40 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.86 | 2024 | Tecnis Simplicity |
| Harrow Eye, LLC | $16.83 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.